Biohaven adds nearly $1B in Nurtec deals with Royalty Pharma, Sixth Street
Biohaven just added nearly $1 billion to their balance sheet.
On Friday morning, the neuroscience biotech announced a pair of creative agreements with Royalty …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
